Denali(DNLI) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – November 6, 2025 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. "Momentum is building across Denali as we prepare for the anticipated launch of tividenofusp alfa with an experienced and focused commercial team in place," said Ryan Watts, Ph.D., Chief Executive Officer ...